Intellia Therapeutics' stock soared 5.07% during intraday trading on Thursday, following the release of its fourth quarter and full-year 2025 financial results.

The biotech company reported a significant earnings and revenue beat for the quarter. Intellia posted a loss of $0.83 per share, which surpassed analyst expectations. Quarterly sales of $23.017 million also dramatically exceeded estimates, representing a substantial year-over-year increase. Beyond the financial performance, the company provided encouraging updates on its clinical pipeline, including anticipated Phase 3 data for its lonvo-z treatment and the recent lifting of an FDA clinical hold on another key trial.

The positive results and pipeline progress have bolstered investor confidence, with the company noting a strong cash position expected to fund operations into the second half of 2027. Analyst commentary following the report has also been generally positive, contributing to the stock's upward movement during the trading session.